Medicenna Therapeutics Corp (TO:MDNA) — Stock Price
Medicenna Therapeutics Corp (TO:MDNA) is currently trading at CA$0.40 CAD, up 5.33% today. Over the past 52 weeks, shares have ranged between CA$0.35 and CA$1.64. This page tracks Medicenna Therapeutics Corp's live share price on the TO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Medicenna Therapeutics Corp market capitalisation.
Medicenna Therapeutics Corp (MDNA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Medicenna Therapeutics Corp's daily closing share price and trading volume on the TO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Medicenna Therapeutics Corp Income Statement — Revenue, Profit & Earnings by Year
Medicenna Therapeutics Corp's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 |
| Cost of Revenue | CA$55.00K | CA$5.00K | CA$5.00K | CA$38.00K | CA$40.00K |
| Gross Profit | CA$-55.00K | CA$-5.00K | CA$-5.00K | CA$-38.00K | CA$-40.00K |
| Research & Development | CA$15.67 Million | CA$11.79 Million | CA$9.30 Million | CA$14.72 Million | CA$10.87 Million |
| SG&A | CA$5.91 Million | CA$7.87 Million | CA$6.99 Million | CA$7.72 Million | CA$6.49 Million |
| Total Operating Expenses | CA$21.58 Million | CA$19.66 Million | CA$16.30 Million | CA$22.47 Million | CA$17.39 Million |
| Operating Income | CA$-21.63 Million | CA$-19.66 Million | CA$-21.64 Million | CA$-22.30 Million | CA$-17.19 Million |
| EBITDA | CA$-12.97 Million | CA$-18.67 Million | CA$-16.30 Million | CA$-22.54 Million | CA$-17.25 Million |
| EBIT | CA$-13.03 Million | CA$-18.68 Million | CA$-16.30 Million | CA$-22.58 Million | CA$-17.29 Million |
| Interest Expense | — | — | CA$11.60 Million | CA$69.00K | CA$0.00 |
| Income Before Tax | CA$-13.03 Million | CA$-25.47 Million | CA$-10.05 Million | CA$-22.58 Million | CA$-17.29 Million |
| Income Tax Expense | CA$-1.23 Million | — | CA$-11.60 Million | CA$69.00K | CA$-106.00K |
| Net Income | CA$-11.80 Million | CA$-25.47 Million | CA$1.55 Million | CA$-22.65 Million | CA$-17.18 Million |
Medicenna Therapeutics Corp Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Medicenna Therapeutics Corp's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CA$28.38 Million | CA$19.13 Million | CA$36.45 Million | CA$23.46 Million | CA$42.25 Million |
| Total Current Assets | CA$28.17 Million | CA$19.08 Million | CA$36.38 Million | CA$23.39 Million | CA$42.15 Million |
| Cash & Equivalents | CA$24.84 Million | CA$16.98 Million | CA$33.60 Million | CA$20.54 Million | CA$30.38 Million |
| Short-term Investments | — | — | — | CA$0.00 | CA$10.01 Million |
| Net Receivables | CA$2.69 Million | CA$1.16 Million | CA$855.00K | CA$1.31 Million | CA$410.00K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | CA$159.00K | — | — | CA$0.00 | CA$32.00K |
| Goodwill | — | — | CA$60.94K | CA$64.94K | CA$70.93K |
| Total Liabilities | CA$9.29 Million | CA$13.94 Million | CA$6.96 Million | CA$2.62 Million | CA$4.11 Million |
| Total Current Liabilities | CA$4.43 Million | CA$2.86 Million | CA$3.80 Million | CA$2.62 Million | CA$4.11 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | CA$-24.67 Million | CA$-16.98 Million | CA$-33.60 Million | CA$-20.54 Million | CA$-30.34 Million |
| Total Stockholder Equity | CA$19.09 Million | CA$5.19 Million | CA$29.49 Million | CA$20.84 Million | CA$38.15 Million |
| Retained Earnings | CA$-118.25 Million | CA$-106.45 Million | CA$-80.98 Million | CA$-70.93 Million | CA$-48.36 Million |
Medicenna Therapeutics Corp Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Medicenna Therapeutics Corp generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-16.49 Million | CA$-16.26 Million | CA$-12.66 Million | CA$-23.58 Million | CA$-15.31 Million |
| Capital Expenditures | CA$33.00K | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 |
| Free Cash Flow | CA$-16.52 Million | CA$-16.26 Million | CA$-12.66 Million | CA$-23.58 Million | CA$-15.31 Million |
| Investing Cash Flow | CA$-33.00K | — | CA$-13.05 Million | CA$10.05 Million | CA$5.01 Million |
| Financing Cash Flow | CA$23.49 Million | CA$0.00 | CA$24.76 Million | CA$3.88 Million | CA$18.26 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CA$2.21 Million | CA$1.21 Million | CA$1.37 Million | CA$1.42 Million | CA$1.01 Million |
| Depreciation | CA$53.00K | CA$4.00K | CA$4.00K | CA$38.00K | CA$40.00K |
| Change in Cash | CA$7.86 Million | CA$-16.61 Million | CA$13.06 Million | CA$-9.84 Million | CA$7.68 Million |
Medicenna Therapeutics Corp Earnings History — EPS Actual vs. Analyst Estimates
Track Medicenna Therapeutics Corp's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 24, 2026 | — | -0.06 | — |
| Feb 12, 2026 | -0.05 | -0.06 | +16.67% |
| Nov 12, 2025 | -0.06 | -0.07 | +14.29% |
| Jul 29, 2025 | -0.06 | -0.05 | -20.00% |
| Jun 25, 2025 | 0.02 | -0.05 | +140.00% |
| Feb 12, 2025 | -0.07 | -0.07 | +0.00% |
| Nov 14, 2024 | -0.05 | -0.06 | +16.67% |
| Jul 31, 2024 | -0.05 | -0.06 | +16.67% |